相似文献
1
Ribosomal mutations conferring resistance to macrolides in Streptococcus pneumoniae clinical strains isolated in Germany.
Antimicrob Agents Chemother. 2003 Jul;47(7):2319-22. doi: 10.1128/AAC.47.7.2319-2322.2003.
2
Macrolide resistance mechanisms among Streptococcus pneumoniae isolated over 6 years of Canadian Respiratory Organism Susceptibility Study (CROSS) (1998 2004).
J Antimicrob Chemother. 2007 Oct;60(4):733-40. doi: 10.1093/jac/dkm273. Epub 2007 Aug 2.
3
Diversity of ribosomal mutations conferring resistance to macrolides, clindamycin, streptogramin, and telithromycin in Streptococcus pneumoniae.
Antimicrob Agents Chemother. 2002 Jan;46(1):125-31. doi: 10.1128/AAC.46.1.125-131.2002.
4
Macrolide resistance by ribosomal mutation in clinical isolates of Streptococcus pneumoniae from the PROTEKT 1999-2000 study.
Antimicrob Agents Chemother. 2003 Jun;47(6):1777-83. doi: 10.1128/AAC.47.6.1777-1783.2003.
5
Time-kill study of the activity of telithromycin against macrolide-resistant Streptococcus pneumoniae Isolates with 23S rRNA mutations and changes in ribosomal proteins L4 and L22.
Antimicrob Agents Chemother. 2005 Jul;49(7):3011-3. doi: 10.1128/AAC.49.7.3011-3013.2005.
6
Two new mechanisms of macrolide resistance in clinical strains of Streptococcus pneumoniae from Eastern Europe and North America.
Antimicrob Agents Chemother. 2000 Dec;44(12):3395-401. doi: 10.1128/AAC.44.12.3395-3401.2000.
7
Mutations in 23S rRNA and ribosomal protein L4 account for resistance in pneumococcal strains selected in vitro by macrolide passage.
Antimicrob Agents Chemother. 2000 Aug;44(8):2118-25. doi: 10.1128/AAC.44.8.2118-2125.2000.
8
Mutations in 23S rRNA account for intrinsic resistance to macrolides in Mycoplasma hominis and Mycoplasma fermentans and for acquired resistance to macrolides in M. hominis.
Antimicrob Agents Chemother. 2002 Oct;46(10):3142-50. doi: 10.1128/AAC.46.10.3142-3150.2002.
9
Predominance of 23S rRNA mutants among non-erm, non-mef macrolide-resistant clinical isolates of Streptococcus pneumoniae collected in the United States in 1999-2000.
Antimicrob Agents Chemother. 2005 Jul;49(7):3031-3. doi: 10.1128/AAC.49.7.3031-3033.2005.
10
Heterogeneous macrolide resistance and gene conversion in the pneumococcus.
Antimicrob Agents Chemother. 2006 Jan;50(1):359-61. doi: 10.1128/AAC.50.1.359-361.2006.
引用本文的文献
1
An Overview of Macrolide Resistance in Streptococci: Prevalence, Mobile Elements and Dynamics.
Microorganisms. 2022 Nov 23;10(12):2316. doi: 10.3390/microorganisms10122316.
2
Bacterial Resistance to Antimicrobial Agents.
Antibiotics (Basel). 2021 May 17;10(5):593. doi: 10.3390/antibiotics10050593.
3
High Frequency of Macrolide-Resistant Colonization in Respiratory Tract of Healthy Children in Ardabil, Iran.
Tanaffos. 2019 Feb;18(2):118-125.
4
Ketolides--the modern relatives of macrolides : the pharmacokinetic perspective.
Clin Pharmacokinet. 2009;48(1):23-38. doi: 10.2165/0003088-200948010-00002.
5
Multidrug-resistant Streptococcus pneumoniae infections: current and future therapeutic options.
Drugs. 2007;67(16):2355-82. doi: 10.2165/00003495-200767160-00005.
6
Frequency of development and associated physiological cost of azithromycin resistance in Chlamydia psittaci 6BC and C. trachomatis L2.
Antimicrob Agents Chemother. 2007 Dec;51(12):4267-75. doi: 10.1128/AAC.00962-07. Epub 2007 Oct 1.
7
Clonal spread of mef-positive macrolide-resistant Streptococcus pneumoniae isolates causing invasive disease in adults in Germany.
Antimicrob Agents Chemother. 2007 May;51(5):1830-4. doi: 10.1128/AAC.01453-06. Epub 2007 Feb 26.
8
High-level telithromycin resistance in a clinical isolate of Streptococcus pneumoniae.
Antimicrob Agents Chemother. 2007 Mar;51(3):1092-5. doi: 10.1128/AAC.01153-06. Epub 2007 Jan 8.
9
Telithromycin-nonsusceptible clinical isolates of Streptococcus pneumoniae from Europe.
Antimicrob Agents Chemother. 2006 Nov;50(11):3897-900. doi: 10.1128/AAC.00057-06.
10
Macrolide efflux in Streptococcus pneumoniae is mediated by a dual efflux pump (mel and mef) and is erythromycin inducible.
Antimicrob Agents Chemother. 2005 Oct;49(10):4203-9. doi: 10.1128/AAC.49.10.4203-4209.2005.
本文引用的文献
1
Macrolide-resistant Streptococcus pneumoniae and Streptococcus pyogenes in the pediatric population in Germany during 2000-2001.
Antimicrob Agents Chemother. 2003 Feb;47(2):489-93. doi: 10.1128/AAC.47.2.489-493.2003.
2
A novel efflux system in inducibly erythromycin-resistant strains of Streptococcus pyogenes.
Antimicrob Agents Chemother. 2002 Dec;46(12):3750-5. doi: 10.1128/AAC.46.12.3750-3755.2002.
3
Increasing prevalence of antimicrobial resistance among isolates of Streptococcus pneumoniae from the PROTEKT surveillance study, and compatative in vitro activity of the ketolide, telithromycin.
J Antimicrob Chemother. 2002 Sep;50 Suppl S1:25-37. doi: 10.1093/jac/dkf808.
4
Antistreptococcal activity of telithromycin compared with seven other drugs in relation to macrolide resistance mechanisms in Russia.
Antimicrob Agents Chemother. 2002 Sep;46(9):2963-8. doi: 10.1128/AAC.46.9.2963-2968.2002.
5
Resistance to macrolides and related antibiotics in Streptococcus pneumoniae.
Antimicrob Agents Chemother. 2002 Sep;46(9):2727-34. doi: 10.1128/AAC.46.9.2727-2734.2002.
6
Will resistance to ketolides develop in Streptococcus pneumoniae?
J Infect. 2002 Feb;44 Suppl A:11-6.
7
Emergence of macrolide resistance during treatment of pneumococcal pneumonia.
N Engl J Med. 2002 Feb 21;346(8):630-1. doi: 10.1056/NEJM200202213460820.
8
Ribosomal mutations in Streptococcus pneumoniae clinical isolates.
Antimicrob Agents Chemother. 2002 Mar;46(3):654-8. doi: 10.1128/AAC.46.3.654-658.2002.
9
Susceptibilities to telithromycin and six other agents and prevalence of macrolide resistance due to L4 ribosomal protein mutation among 992 Pneumococci from 10 central and Eastern European countries.
Antimicrob Agents Chemother. 2002 Feb;46(2):371-7. doi: 10.1128/AAC.46.2.371-377.2002.
10
Emergence of macrolide and penicillin resistance among invasive pneumococcal isolates in Germany.
J Antimicrob Chemother. 2002 Jan;49(1):61-8. doi: 10.1093/jac/49.1.61.
Zotero 插件